Skip to main content
. Author manuscript; available in PMC: 2011 Feb 15.
Published in final edited form as: Exp Cell Res. 2009 Dec 16;316(4):507. doi: 10.1016/j.yexcr.2009.12.004

Fig. 6.

Fig. 6

Role of the ERK1/2 and JNK1/2 pathway in PMA-induced expression of ANGPTL4. (A) HASM cells were treated with the p38 inhibitors PD169316 (5 μM) or with the MEK/ERK inhibitor U0126 (10 μM) 30 min before the addition of 30 nM PMA. After 6 h, cells were collected for RNA isolation and examined by Northern blot analysis for ANGPTL4 expression. The results shown are representative of two independent experiments. (B) MEK and JNK inhibitors block PMA-induced ANGPTL4 mRNA expression in HLF cells. Cells were pretreated with MEK inhibitor U0126 (10 μM), p38 inhibitor SB203580 (10 μM), and JNK inhibitor SP600125 (10 μM) for 30 min prior to the addition of PMA (30 nM). After 6 h of treatment, cells were collected for RNA isolation. Expression of ANGPTL4 mRNA was examined by QRT-PCR. (C) HASM cells were pretreated for 30 min with 10 μM of the JNK inhibitor SP600125 prior to the addition of 30 nM PMA. After 6 h incubation, total RNA was isolated and ANGPTL4 expression examined by QRT-PCR analysis.